-
New CEO unveils Apple's first foldable iPhone
-
Cyberattack ruled out in UK air traffic glitch that hit hundreds of flights
-
Rubio pushes anti-drug fight in Ecuador
-
Ogura to miss San Marino MotoGP with hand injury
-
England on top in third Test after historic Pakistan collapse
-
Noosha Aubel, CDU och SPD: Fallet med ett svårt funktionshindrat barn i Potsdam är ett politiskt misslyckande
-
Noosha Aubel, CDU a SPD: Případ těžce postiženého dítěte v Postupimi je politickým přiznáním bankrotu
-
Noosha Aubel, CDU and SPD: The case of a severely disabled child in Potsdam is a political admission of failure
-
Нооша Аубель, ХДС и СДПГ: Случай с ребенком с тяжелой формой инвалидности в Потсдаме — это признание политического банкротства
-
Нооша Аубель, ХДС та СДПН: Випадок з дитиною з тяжкою інвалідністю в Потсдамі є визнанням політичного банкрутства
-
نوشا أوبيل، حزب الاتحاد الديمقراطي المسيحي (CDU) والحزب الاشتراكي الديمقراطي (SPD): قضية طفل يعاني من إعاقة شديدة في بوتسدام هي إعلان إفلاس سياسي
-
Noosha Aubel, CDU ve SPD: Potsdam’daki ağır engelli bir çocuğun durumu, siyasi bir iflas ilanıdır
-
Noosha Aubel, CDU i SPD: Sprawa ciężko niepełnosprawnego dziecka w Poczdamie to polityczne przyznanie się do porażki
-
Noosha Aubel, CDU και SPD: Η υπόθεση ενός παιδιού με σοβαρή αναπηρία στο Πότσδαμ αποτελεί πολιτική παραδοχή αποτυχίας
-
नूशा ऑबेल, सीडीयू और एसपीडी: पॉट्सडैम में एक गंभीर रूप से विकलांग बच्चे का मामला, विफलता की एक राजनीतिक स्वीकारोक्ति है
-
누샤 아우벨, 기민당(CDU) 및 사민당(SPD): 포츠담의 중증 장애 아동 사건은 정치적 파산을 선언한 것과 다름없다
-
努莎·奧貝爾(Noosha Aubel)、基民盟(CDU)與社民黨(SPD):波茨坦一名重度殘障兒童的案例,等同於政治上的破產宣言
-
ヌーシャ・オーベル、CDUおよびSPD:ポツダムで起きた重度障害児の事例は、政治的な破綻を露呈している
-
Josh Kerr: I pick my races and I'm not a robot
-
Rybakina ensures rise to No.1 by reaching US Open semis
-
Apple unveils its first foldable smartphone iPhone Duo
-
Evacuations in Malibu after waves open sinkhole at Nicolas Cage's house
-
Rampant Raphinha bags brace as Barcelona rout Feyenoord
-
England on top in third Test after latest Pakistan collapse
-
Rybakina ensures rise to world no. 1 by reaching US Open semis
-
England edge ahead in third Test after latest Pakistan collapse
-
How hot can the US-Canada trade war get?
-
'Alarm bells ringing': US summer heat shatters record
-
Iran strikes ships, expands no-go zone outside Hormuz strait
-
IAEA board refers Iran to UN Security Council
-
'Gambling with our lives': AI researcher quits Anthropic
-
Rubio pushes extraditions, anti-drug fight in Ecuador
-
Belgium raids illicit cigarette factory in push to stub out growing trade
-
Amboss and Aureo Connect the Lightning Network to Mexico's Banking System
-
Vuelta debutant Brennan claims fifth victory on stage 17
-
Brent oil passes $100 on Mideast flare-up, stoking inflation fears
-
US had warmest summer on record: climate agency
-
Israeli settlement winemaker defiant after UK-led trade sanctions
-
Meta tests fact-check replacement in Latin America
-
Josh Kerr: I pick my races and never get 'greedy'
-
Soviet brutality, ideology backdrop of controversial Venice film
-
Carrick confident Man Utd can go far in 'magical' Champions League
-
McIlroy predicts player exodus after LIV files for bankruptcy protection
-
France far right expels policeman member over racist remarks
-
Global Multi-Asset Broker FP Markets Secures UAE CMA Category 5 Licence
-
Pakistan collapse to 133 all out against England in 3rd Test
-
Brent oil passes $100 on Mideast flare-up, stoking inflation worries
-
Heat forces French champagne makers to stiffen their drink
-
'Nothing left': thousands in Yemen flee deadly Houthi clashes
-
Iran war drives oil prices to $100 per barrel as Tehran strikes ships
Pfizer profits drop on lower Covid-19 product sales
Pfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and implements previously announced cost cuts.
Much lower sales of Covid-19 vaccine Comirnaty and therapeutic Paxlovid accounted for a 20 percent drop in first-quarter revenues to $14.9 billion compared with the year-ago period.
Profits were $3.1 billion, down 44 percent.
The drugmaker pointed to increased sales of oncology products, in part driven by the acquisition of Seagen, which was completed in December.
Other products with significant growth included Vyndaquel, which is used to treat nerve disease; Eliquis, which treats blood clots; and Prevnar, a vaccine for pneumonia.
"I am very pleased by the strong 11 percent operational revenues growth of our non-Covid products in the first quarter," said Chief Financial Officer David Denton.
"We continue to progress our cost realignment program and remain on track to deliver on our targeted goal by the end of the year."
Pfizer said it will deliver "at least" $4 billion in savings by the end of 2024.
The company, which raised its earnings per share projection, has maintained a shareholder dividend. However, it plans no share repurchases in 2024 in favor of pumping funds back into research and development to support the drug pipeline.
Shares of Pfizer rose 1.3 percent in pre-market trading.
O.Ortiz--AT